Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume Sells 4,400 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Charles River Laboratories International Stock Up 0.5 %

Shares of NYSE CRL opened at $163.11 on Friday. The company’s 50-day simple moving average is $172.84 and its 200-day simple moving average is $188.37. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $275.00. The firm has a market cap of $8.34 billion, a price-to-earnings ratio of 1,087.39, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the business earned $2.46 earnings per share. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CRL. UBS Group reiterated a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Bank of America dropped their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Finally, Morgan Stanley dropped their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $195.71.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently modified their holdings of the business. Versant Capital Management Inc lifted its stake in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares in the last quarter. Assetmark Inc. lifted its stake in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. Optiver Holding B.V. purchased a new position in shares of Charles River Laboratories International in the fourth quarter worth about $37,000. Finally, GeoWealth Management LLC lifted its stake in shares of Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after buying an additional 190 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).